Abstract 2342
Background
The FIRSTANA trial compared docetaxel 75mg/m2 Q3W (D75), cabazitaxel 20mg/m2 Q3W (C20) and cabazitaxel 25mg/m2 Q3W (C25) in patients with chemo-naive mCRPC (Oudard 2017). FIRSTANA enrolled patients regardless of presence of disease-related symptoms. This post-hoc analysis of FIRSTANA evaluates the influence of progression type on outcomes.
Methods
Patient outcomes (OS, PSA response [confirmed PSA decline from baseline ≥ 50%] and radiological PFS [rPFS]) were analyzed according to progression type at randomization. Progression at randomization was defined as follows: PSA progression only (PSA-p) with no radiological progression (Radio-p) and no pain, Radio-p (± PSA-p, no pain), pain progression (mean Present Pain Intensity ≥2 and/or mean analgesic score ≥ 10 over the 7 days prior to randomization (±PSA-p, ±Radio-p).
Results
PSA-p, Radio-p and Pain-p were present in 34.4%, 23.2% and 42.3% of patients at randomization, respectively. Pain progression at initiation of chemotherapy was associated with features of aggressive disease and a shorter OS. Lower activity of C20 than C25 and D75 was observed in patients with Pain-p.Table:
859P
Progression type | ||||
---|---|---|---|---|
PSA-p N = 362 | Radio-p N = 244 | Pain-p N = 445 | Global p° | |
- PSA decrease ≥ 50% - Overall - D75 - C20 - C25 | 69.0% 67.4% 71.0% 69.0% | 69.8% 65.8% 66.2% 78.3% | 58.0% 62.2% 49.3% 63.0% | P = 0.003 P = 0.70 P = 0.002 P = 0.21 |
-rPFS, median [95% CI]* - Overall - D75 - C20 - C25 | 16.5 [14.3; 18.9] 13.5 [11.3; 16.7] 19.7 [14.3; 26.5] 18.2 [14.2; 22.6] | 12.1 [11.2; 14.4] 11.3 [9.7; 14.4] 13.4 [10.6; 22.8] 11.4 [10.1; 15.7] | 10.8 [9.3;11.6] 11.4 [8.8; 13.9] 9.1 [7.6; 10.9] 11.1 [9.7; 12.8] | p < 0.001 p = 0.13 p < 0.001 p = 0.001 |
OS, median [95% CI]* - Overall - D75 - C20 - C25 | 27.7 [25.4;31.2] 29.0 [22.6; 36.6] 30.0 [24.9; NR] 26.5 [24.0; 31.6] | 30.6 [26.8;34.3] 28.4 [22.0; 34.1] 32.1 [27.9; 41.4] 29.7 [24.0; 38.5] | 18.5 [16.8; 20.6] 20.3[16.5;24.3] 16.5[14.3; 19.1] 20.4[17.0;25.3] | p < 0.001 p = 0.003 p < 0.001 p = 0.031 |
in months, NR: not reached; °Log rank test for rPFS and OS, CMH test adjusted on stratification factors
Conclusions
Most patients in FIRSTANA had pain progression at randomization and this factor was associated with worse OS. In this post-hoc, subgroup analysis, C20 appeared less active than D75 and C25 in men with baseline pain progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nicolas Delanoy.
Funding
Sanofi.
Disclosure
N. Delanoy: Travel / Accommodation / Expenses: Sanofi; Honoraria (self): Tesaro; Honoraria (self): MSD. D. Robbrecht: Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy: Bayer. K. Fizazi: Honoraria (self): Amgen; Honoraria (self): Astellas; Honoraria (self): AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Clovis; Honoraria (self): CureVac; Honoraria (self): Essa; Honoraria (self): Genentech; Honoraria (self): Janssen; Honoraria (self): MSD; Honoraria (self): Orion; Honoraria (self): Sanofi. F. Mercier: Honoraria (self): Sanofi; Honoraria (self): AstraZeneca; Shareholder / Stockholder / Stock options, Stat Process is a CRO providing statistical services to various companies: Stat Process. O. Sartor: Shareholder / Stockholder / Stock options: Eli Lilly; Shareholder / Stockholder / Stock options: GlaxoSmithKline; Shareholder / Stockholder / Stock options: Noria; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy: Bellicum; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Johnson &Johnson; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Dendreon; Advisory / Consultancy, Research grant / Funding (institution): Endocyte; Advisory / Consultancy: Constellation Pharmaceuticals; Advisory / Consultancy: Advanced Accelerator Applications; Advisory / Consultancy: Pfizer; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Bavarian Nordic; Advisory / Consultancy: Oncogenex; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Astellas; Advisory / Consultancy, Travel / Accommodation / Expenses: Progenics. R. de Wit: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genentech. S. Oudard: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Honoraria (self): Bayer; Honoraria (self): Pfizer; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): BMS; Honoraria (self): Ipsen.
Resources from the same session
2927 - Singapore Caregiver Quality Of Life Scale (SCQOLS): Turkish Validity and Reliability Study
Presenter: Nur Basak
Session: Poster Display session 3
Resources:
Abstract
5066 - Screening for Psicosocial Distress in recently diagnosed cancer patients
Presenter: Eva Baillès
Session: Poster Display session 3
Resources:
Abstract
6074 - Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a Primary Care Center.
Presenter: Begona Grana Suarez
Session: Poster Display session 3
Resources:
Abstract
5129 - The adhesion in the screening measures in carrying patients of breast cancer and ovary hereditary and the relationship with the psychological aspects
Presenter: Melinda Concepcion
Session: Poster Display session 3
Resources:
Abstract
5635 - Assessment of emotional discomfort of oncological patients in the first nursing visit at Donostia University Hospital
Presenter: Elena Uranga
Session: Poster Display session 3
Resources:
Abstract
858 - A systematic review and meta-analysis of the distress thermometer for the screening of distress in Chinese patients with cancer
Presenter: Hui Hui Sun
Session: Poster Display session 3
Resources:
Abstract
4475 - Pharmacist and Nurse (PN) Led Melanoma Immunotherapy Clinic: Patient Experience Survey
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
1871 - Phone Triage & Acute Review Clinics: The emerging role of the Oncology Specialist Nurse
Presenter: Fiona Barrett
Session: Poster Display session 3
Resources:
Abstract
5193 - Patient reported outcomes during immunotherapy: symptom burden in daily clinical practice
Presenter: José Koldenhof
Session: Poster Display session 3
Resources:
Abstract
2453 - Factors related to hospital length of stay, re-admissions and unplanned care for patients with cancer, an on-going study
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract